Can Biogen Idec keep the hits coming? The biotech giant's stock has been at the top of the charts among its peers over the past year, helped considerably by its experimental multiple sclerosis drug BG-12's performance in late-stage development.
With new Phase III data on the potential blockbuster expected within weeks, analysts told Reuters about some of the key factors that could play a role in the success of oral drug in the MS market.
Biogen, the world's largest provider of MS therapies, is banking on BG-12 to enter the new market for oral drugs against relapses of the nerve-damaging disease, which is most often treated with injected meds. The company's Phase III trial--dubbed DEFINE--impressed earlier this year, showing the drug could reduce annualized relapse rates 53% compared with placebo, Reuters reports. And drug has the potential to offer better safety than Gilenya, Novartis' oral MS pill that gained FDA approval last year.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1679